- Health Canada has granted NOC to Saphnelo (anifrolumab) for subcutaneous self-administration via autoinjector in adults with active, autoantibody-positive SLE alongside standard therapy
- The approval is based on interim Phase 3 TULIP-SC trial data, showing statistically significant and clinically meaningful reductions in disease activity vs placebo
- The SC formulation offers a new, more convenient delivery option, building on the benefits of IV Saphnelo in reducing disease activity and long-term organ damage
- SLE affects ~1 in 1,000 Canadians, primarily women, with higher mortality risk; the new option addresses limitations of corticosteroids, which offer short-term relief without targeting underlying disease drivers
Takeaways:
AstraZeneca deepens its Saphnelo franchise in Canada by adding a self‑administered SC autoinjector on top of IV, improving convenience and persistency in a chronic, mostly female SLE population.
Home‑use SC dosing should reduce infusion‑center dependence and friction for moderate to severe SLE patients, supporting broader uptake versus IV‑only biologics and potentially expanding the treated pool beyond steroid‑anchored regimens.
Source: PRnewswire | Image: AstraZeneca